Relapsed/Refractory Multiple Myeloma: Evolving Treatment Landscape and Sequencing

Dr. Joshua Richter opens the discussion by introducing the objectives of the program, highlighting the evolving treatment landscape of relapsed/refractory multiple myeloma (RRMM) and the increasing importance of individualized treatment strategies. He outlines key topics that will be explored throughout the discussion, including patient selection, risk assessment, treatment sequencing, referral timing, multidisciplinary care, bridging therapy, quality of life, and caregiver support. Transitioning into the scientific discussion, Dr. Richter invites Dr. Marco Davila to describe how the management of RRMM has shifted from simply selecting therapies to strategically sequencing them based on prior treatment exposure, disease biology, refractory status, cytogenetic risk, disease kinetics, and patient-specific psychosocial factors. Dr. Davila also discusses the earlier integration of BCMA-directed therapies, including CAR T-cell therapy and T-cell engagers, emphasizing how emerging phase 3 clinical evidence is reshaping treatment paradigms and enabling durable responses for appropriate patients earlier in the disease course.